Skye Bioscience (FRA:09R0) Other Stockholders Equity: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:09R0 Skye Bioscience Inc FRA:09R0
19 GF Score
Price €1.73
! 2 Warning Signs
View Full Analysis

What is Skye Bioscience Other Stockholders Equity?

Skye Bioscience FRA:09R0 +13.40% 19 Other Stockholders Equity is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:09R0 with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Skye Bioscience's Other Stockholders Equity for the quarter that ended in Jun. 2026 was €0.00 Mil.

Skye Bioscience's quarterly Other Stockholders Equity increased from Dec. 2025 (€-0.00 Mil) to Mar. 2026 (€0.00 Mil) and increased from Mar. 2026 (€0.00 Mil) to Jun. 2026 (€0.00 Mil).

Skye Bioscience's annual Other Stockholders Equity declined from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) and declined from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Skye Bioscience Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Skye Bioscience's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skye Bioscience Other Stockholders Equity Chart

Skye Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00

Skye Bioscience Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.00
FRA:09R0
19GF Score
Skye Bioscience Inc FRA:09R0
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Skye Bioscience Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0.00 Mil mean?
Skye Bioscience (FRA:09R0) has a Other Stockholders Equity of €0.00 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Skye Bioscience and its competitors.
Is Skye Bioscience's Other Stockholders Equity too high?
Skye Bioscience's current Other Stockholders Equity is €0.00 Mil. Overall, Skye Bioscience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's Other Stockholders Equity compare to ATOS and JSPR?
Skye Bioscience's Other Stockholders Equity of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Skye Bioscience and its competitors. Skye Bioscience's current Other Stockholders Equity is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (FRA:09R0) has a current Other Stockholders Equity of €0.00 Mil. The current Other Stockholders Equity is €0.00 Mil. Skye Bioscience's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Skye Bioscience (FRA:09R0), the current Other Stockholders Equity is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Skye Bioscience Business Description

Other Exchanges SKYE:USA
Address 11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
19GF Score

Get the complete analysis for FRA:09R0

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.73
Price